Vorabbekanntmachung Finanzberichte gemäß § 37v,w,x WpHG
Durchführung der Barkapitalerhöhung: Bruttoemissionserlös beträgt rund EUR 2,6 Mio.
Veröffentlichung gemäß § 93 Abs. 2 BörseG
Vorabbekanntmachung Finanzberichte gemäß § 37v,w,x WpHG
Halbjahresfinanzbericht gemäß § 87 Abs. 1 BörseG
CA Immo begibt Wandelschuldverschreibungen
Veröffentlichung des Halbjahresberichts 2017
MELDUNG VOM 07.07.2017 15:08
Meldung drucken Artikel weiterleiten
Business news for the stock market
Pressefach Pressefach

HAEMATO AG: Change in Management Board

Schönefeld (pta019/07.07.2017/15:08) - In today's meeting, the Supervisory Board of HAEMATO AG ("HAEMATO" or the "Company") accepted the wish of Dr. Christian Pahl to not extend his contract as Management Board Member beyond the current term ending 31 July 2017. The Supervisory Board regrets this decision. Dr. Pahl has been a member of the Management Board of HAEMATO since May 2012.

Upon leaving the Company at the end of his term on his own request, Dr. Pahl wishes to devote himself to new tasks.

In today's Supervisory Board meeting, Mr. Uwe Zimdars was appointed Chief Executive Officer and Mr. Daniel Kracht was appointed Chief Financial Officer.

Mr. Uwe Zimdars holds a degree in business management and began his career in the Auditing and Management Consulting division of Arthur Andersen. Later, Mr. Zimdars led a large logistics services provider as managing director for several years. His core experiences are in the fields of strategic and operational planning as well as digitalization.

Mr. Daniel Kracht, after his studies of business management, has held several positions in tax advisory and commercial planning. Since 2011, Mr. Kracht has been part of HAEMATO's leadership team as Head of Group Accounting and Controlling. Since 1 January 2017, Mr. Kracht is a member of the Management Board of HAEMATO PHARM GmbH.

Both have extensive experience in the healthcare industry and the Supervisory Board looks forward to a productive cooperation with Mr. Zimdars and Mr. Kracht.


HAEMATO AG, which was founded in 1993, is a pharmaceutical company. The focus of the operational activities is on the growth markets of patent-free and patent-protected pharma-ceuticals. Focal points are therapies of cancer, HIV, and other chronic diseases.


Aussender: HAEMATO AG
Lilienthalstraße 5c
12529 Schönefeld
Ansprechpartner: Dr. Christian Pahl
Tel.: +49 30 8973086-70
ISIN(s): DE0006190705 (share)
Börsen: free market in Dusseldorf, basic board in Frankfurt, free market in Hamburg, free market in Stuttgart; open market in Berlin, Tradegate